Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.

ABSTRACT:

Background

The clinical benefit of a selective cyclooxygenase-2 inhibitor, celecoxib, combined with anticancer therapy in advanced non-small-cell lung cancer (NSCLC) remains unclear. A meta-analysis was performed to address the efficacy and safety of celecoxib in patients with advanced NSCLC.

Materials and methods

Three databases, including PubMed, EMBASE, and the Cochrane Library, were systematically searched for available literature until March 1, 2018. Data on tumor response rates, one-year survival, overall survival, progression-free survival, and toxicities were extracted from the included randomized clinical trials. Subgroup analysis was carried out according to the line of treatment. Review Manager 5.3 software was applied to conduct the meta-analysis.

Results

SUBMITTER: Yi L 

PROVIDER: S-EPMC6086108 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature